1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Emcure Pharmaceuticals Limited

Emcure Pharmaceuticals Limited

1,785.05
INR
+29.10
(+1.66%)
53.75EPS
34.60P/E
350.13BMarket Cap
Nov 03Next Earn
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
275.76
318.94
328.06
364.21
417.46
480.96
510.81
Basic EPS, GAAP
21.69
36.63
29.43
27.57
36.43
48.77
53.35
Free Cash Flow per Basic Share
30.91
20.53
19
43.72
23.78
20.89
- -
Dividend per Share
1
3
2
3
- -
3
- -
Book Value per Share
120.2
105.11
132.27
156.12
234.65
261.09
- -
Tangible Book Value per Share
78.92
85.08
114.1
109.25
184.67
203.01
- -
Basic Weighted Avg Shares
181
181
181
181
187
190
190
Sales/Revenue/Turnover
49,856
57,662
59,311
65,820
78,083
91,159
96,835
Operating Margin (%)
19.43
18.86
15.86
13.94
13.89
15.07
15.16
Depreciation Expense
3,233
2,449
2,601
3,124
3,841
4,150
4,251
Net Income, GAAP
3,921
6,622
5,320
4,982
6,813
9,244
10,114
Effective Tax Rate (%)
27.77
27.76
24.81
27.45
27.17
26.87
26.69
Profit Margin (%)
7.87
11.48
8.97
7.57
8.73
10.14
10.44
Working Capital
3,093
4,593
8,167
10,494
18,876
16,999
- -
LT Debt
8,208
8,286
8,593
9,823
4,473
5,145
- -
Total Equity
23,680
21,141
26,497
31,218
46,416
49,767
- -
Return on Invested Capital (%)
- -
17.03
14.73
12.72
14.56
15.62
- -
Return on Capital (%)
- -
15.65
13.41
11.77
13.62
16.41
- -
Return on Common Equity (%)
- -
31.09
23.7
18.27
18.42
19.68
- -

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
10,068
- -
LT Borrowings
- -
2,522
- -
LT Finance Leases
- -
2,623
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
190
190
190
Market Capitalization
258,615
302,575
350,134

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
56,121
- -
Cash, Cash Equivalents & STI
- -
1,828
- -
Accounts Receivable, Net
- -
25,627
- -
Inventories
- -
23,979
- -
Total Current Liabilities
- -
39,122
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
10,068
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
17.67%
7.22%
Free Cash Flow
- -
6.86%
-11%
Net Income, GAAP
- -
23.06%
35.67%
Sales/Revenue/Turnover
- -
12.97%
16.75%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
18,151
20,020
19,626
21,162
78,083
2026
21,005
22,698
23,635
24,697
91,159
2027
25,804
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
7.62
10.38
8.12
9.97
36.43
2026
10.92
12.85
12.16
12.84
48.77
2027
15.5
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
3
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Satish Ramanlal Mehta
Full Time Employees
6,914
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Plot No. P-1 and P-2 Pune MA India 411057
IPO Date
Jul 10, 2024
Website
emcure.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Emcure Pharmaceuticals Ltd. (EMCURE.NS) develops, manufactures and markets a broad portfolio of pharmaceutical products across major therapeutic areas including gynaecology, cardiology, nephrology, oncology, HIV antivirals, blood-related treatments, anti-infectives, pain and analgesics, diabetes management, respiratory, hormones and anti-diabetics; offers differentiated formulations such as complex generics, biosimilars, vaccines, monoclonal antibodies, orals including tablets, capsules, soft-gelatin capsules and solid orals, injectables, active pharmaceutical ingredients, syrups, eye drops, solutions, ointments and pessaries; leads the Indian market in gynaecology with a 13.53% share and HIV antivirals while ranking as the 13th largest by domestic sales and fourth by market share in covered markets as of FY24. Founded in 1981 and headquartered in Pune, India, at Plot No. P-1 and P-2, IT-BT Park, Phase II, M.I.D.C., Hinjawadi, the company operates 13 advanced manufacturing facilities and five state-of-the-art R&D centers across India including US FDA-approved sites at Kurkumbh for APIs, Sanand and Jammu for solids, and a biotech facility at Hinjawadi, plus a manufacturing and R&D center in East Brunswick, New Jersey, USA; sells products in over 70 countries with international revenues at 51.72% of total in FY24, emphasizing strong presence in Europe, Canada, North America, Middle East, APAC and India through its own distribution and alliances with local and multinational partners. In July 2024, Emcure completed its initial public offering on BSE and NSE raising Rs 1,952 crore including a fresh issue of Rs 800 crore for debt repayment and general purposes; in 2025, the company approved acquisition of the remaining 20.42% stake in subsidiary Zuventus Healthcare for Rs 724.9 crore in cash, expected to close by Q2 FY26, enabling full consolidation, operational synergies and strengthened domestic market leadership across multiple therapeutic segments.